Co-Diagnostics announced that CoSara Diagnostics has received clearance by the CDSCO in India to manufacture and sell its SARAQ™ Hepatitis C Viral Load Kit as an in vitro diagnostic.

Achieved Record Full Year Revenue of $97.9 Million; Strength in Sales Momentum Provides Foundation to Achieve Solid FY’22

Co-Diagnostics, Inc. Makes Strategic Additions to Scientific Advisory Board

Co-Diagnostics announced that its Board of Directors has authorized a share repurchase program that would allow the Company to repurchase up to $30 million of CODX common stock.

SALT LAKE CITY, Feb. 3, 2022 /PRNewswire/ — Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that CoSara Diagnostics Pvt Ltd (“CoSara,” or the “JV”), its joint venture for manufacturing and sales in India, has received clearance by the Central […]

Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced that it will be hosting a booth at the upcoming Life Sciences Day on the Hill on February 16, 2022, at the Utah State Capital Building. It is expected that the conference, […]

Co-Diagnostics, Inc. announced that CoSara Diagnostics Pvt Ltd has received clearance by the Central Drugs Standard Control Organization (“CDSCO”) in India to manufacture and sell its SARAGENE™ Human Papillomavirus High-Risk (HPV-HR) Real-Time PCR test as an in vitro diagnostic (“IVD”)

Definitive merger agreements provide the Company with all existing and future assets, future product iterations, and intellectual property rights of the platform, creating a fully integrated product line and streamlining commercialization

Co-Diagnostics announced that CoSara Diagnostics Pvt Ltd has received clearance by the Central Drugs Standard Control Organization (CDSCO) in India to manufacture and sell its SARAPLEX™ Flu A/Flu B/COVID-19 (ABC) RT-PCR test as an in vitro diagnostic (IVD).

None of the mutations in the Omicron variant interfere with any of the Company’s COVID-19 PCR diagnostic assays

Solid quarterly results highlighted by record revenue of $30.1 million, pre-tax income of $13.6 million and fully diluted EPS of $0.38

Company’s validated test available in the UK following implementation of UKHSA CTDA Regulations